A Hit-to-Lead optimisation programme was carried out on a high throughput screening hit, the thiazolopyrimidine 1, resulting in the discovery of the potent, orally bioavailable CXCR2 antagonist 29.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2005.10.091 | DOI Listing |
Publication Analysis
Top Keywords
discovery potent
8
potent orally
8
orally bioavailable
8
hit-to-lead studies
4
studies discovery
4
bioavailable thiazolopyrimidine
4
thiazolopyrimidine cxcr2
4
cxcr2 receptor
4
receptor antagonists
4
antagonists hit-to-lead
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!